Terazosin (Hytrin) — Competitive Intelligence Brief

Terazosin (Hytrin) (Terazosin (Hytrin)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic receptor antagonist. Area: Cardiovascular.

phase 3 Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor Cardiovascular Small molecule

Target snapshot

Terazosin (Hytrin) (Terazosin (Hytrin)) — Hospital Authority, Hong Kong. Terazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow and reducing symptoms of benign prostatic hyperplasia.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Terazosin (Hytrin) TARGET	Terazosin (Hytrin)	Hospital Authority, Hong Kong	phase 3	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
eye drops (Phenylephrin)	eye drops (Phenylephrin)	Medical University of Graz	marketed	Alpha-1 adrenergic agonist	Alpha-1 adrenergic receptor
placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan	placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan	Montefiore Medical Center	marketed	Combination cold and cough remedy	H1 receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); sigma-1 receptor and NMDA receptor (dextromethorphan)
alpha blocker monotherapy	alpha blocker monotherapy	Samsung Medical Center	marketed	Alpha blocker	alpha-1 adrenergic receptors
CarVeDilol-SR (Slow Release)	CarVeDilol-SR (Slow Release)	Seoul National University Bundang Hospital	marketed	Beta-blocker with alpha-1 blocking activity	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Placebo to Prazosin	Placebo to Prazosin	Brian J Lipworth	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Doxazosin (drug)	Doxazosin (drug)	Japan Heart Foundation	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic receptor antagonist class)

1. Brian J Lipworth · 1 drug in this class
2. CHU de Quebec-Universite Laval · 1 drug in this class
3. Eli Lilly and Company · 1 drug in this class
4. Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 drug in this class
5. Hospital Authority, Hong Kong · 1 drug in this class
6. Japan Heart Foundation · 1 drug in this class
7. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
8. San Francisco Veterans Affairs Medical Center · 1 drug in this class
9. Sanofi · 1 drug in this class
10. Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class